Yorkie Homolog (YAP1) Peptide

Product Graph
175.5€ (100 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Yorkie Homolog (YAP1) Peptide
category
Proteins and Peptides
provider
Abbexa
reference
abx615206
tested applications
P-ELISA

Description

Yorkie Homolog (YAP1) Peptide is a synthetic peptide.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Yorkie Homolog (YAP1)
Host
Synthetic
Recommended Dilution
BL (predicted): 0.5 mg/ml. Optimal dilutions/concentrations should be determined by the end user.
Conjugation
Unconjugated
Observed MW
Sequence Fragment: Internal region: C-TYHSRDESTDS
Size 1
100 µg
Form
Lyophilized Reconstitute in deionized water.
Tested Applications
P-ELISA
Buffer
Prior to lyophilization: Deionized water.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
Gene ID
10413, 22601, 363014
NCBI Accession
NP_006097.1
Background
Protein YAP1
Note
This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

Related Products

EH5221

Human YAP1 (Transcriptional coactivator YAP1) ELISA Kit

Ver Producto
FNab09559

YAP1 antibody

This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms.

Ver Producto
FNab09827

YAP1 antibody

This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms.

Ver Producto